Printer Friendly

Pharming acquires patent portfolio of PPL therapeutics.

Pharming Group N.V. (Leiden, Netherlands) announced that it has acquired the patent portfolio of PPL Therapeutics Ltd. The company has acquired these patents to strengthen its product pipeline and protein production technology.

Pharming has obtained patents and licenses on various products and technologies, including the production and purification of recombinant human fibrinogen and recombinant tissue sealant compositions. In addition, the company has obtained access to processes and know-how for the large scale GMP-grade purification of recombinant human fibrinogen.

"We are pleased to be able to strengthen our recombinant fibrinogen and recombinant tissue sealant products by acquiring PPL patents and processes, which saves the company time and resources in the development of these products." said Dr. Francis Pinto, CEO of Pharming. "In addition, this transaction significantly advances the worldwide patent position of our protein production technology along with recent agreements with Infigen and ProBio and will allow the company to actively pursue licensing and partnering opportunities."

Pharming has also acquired patents on the production of recombinant protein products and production technology patents for proteins, fusion proteins, as well as peptides. The patents cover the production of several recombinant proteins, including Alpha-1-Antitrypsin, Factor IX, and others. In addition, Pharming has taken over certain product and technology licenses that PPL had obtained from third parties.

PPL had established this portfolio over a period of more than 15 years, but recently decided to restructure its commercial focus following a sale of the company. The financial terms of the transaction were not disclosed.

Pharming has acquired 57 issued patents, including 19 in the US as well as several pending patent applications of PPL Therapeutics.

- Patents and licenses obtained cover the production and purification of human recombinant fibrinogen and recombinant tissue sealant compositions.

- Patents in the portfolio include the production of several recombinant proteins such as Alpha-1-Antitrypsin, Bile Salt Stimulated Lipase, Extracellular Superoxide Dismutase, Alpha-lactalbumin and Factor IX. - Patents acquired cover the production technology for recombinant proteins, fusion proteins and peptides.

- Pharming has obtained access to processes and know-how for the large scale GMP grade purification of recombinant fibrinogen.

Pharming is developing innovative protein therapeutics for unmet medical needs. The company's products include potential treatments for genetic disorders and specialty products for surgical indications. Pharming's lead product for Hereditary Angioedema is in Phase III of clinical development. The advanced technologies of the company include novel platforms for the production of protein therapeutics, as well as technology and processes for the purification and formulation of these products.

Pharming Group N.V.

COPYRIGHT 2004 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:Pharming acquires patent portfolio of PPL therapeutics.
Publication:BIOTECH Patent News
Geographic Code:4EUNE
Date:Aug 1, 2004
Previous Article:Key United States patent issues for Agilix GenCompass technology - first microarray-based system enabling gene expression studies where gene sequence...
Next Article:Lexicon extends intellectual property portfolio with patent on gene trapping.

Related Articles
Dolly, Polly, Gene - send in the clones.
Important United States patent secures Pharming's position on human alpha-glucosidase.
Infigen terminates agreement with Pharming Holding.
UPMC, other investors form company to acquire PPL Therapeutics' regenerative medicine business.
Advanced Cell Technology revails in cloning patent dispute.
Sirna Therapeutics obtains patents covering siRNAs targeting VEGF and HCV.
Sirna granted patent covering siRNAs targeting Huntington's Disease.
Sirna granted first broad siRNA patent for a gene target.
European Patent Office limits scope of Kreutzer-Limmer RNAi patent claim.
Introgen receives patent for purified adenoviral compositions.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters